Clinical Trial Detail

NCT ID NCT03157128
Title Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)ET Activation (LIBRETTO-001)er
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Loxo Oncology, Inc.
Indications

thyroid medullary carcinoma

lung non-small cell carcinoma

colon cancer

Advanced Solid Tumor

Therapies

LOXO-292

Age Groups: adult senior

Additional content available in CKB BOOST